Pacira Biosciences Inc banner

Pacira Biosciences Inc
NASDAQ:PCRX

Watchlist Manager
Pacira Biosciences Inc Logo
Pacira Biosciences Inc
NASDAQ:PCRX
Watchlist
Price: 25.105 USD 2.43%
Market Cap: $1B

Pacira Biosciences Inc
PP&E Gross

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Pacira Biosciences Inc
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
Pacira Biosciences Inc
NASDAQ:PCRX
PP&E Gross
$182.5m
CAGR 3-Years
-10%
CAGR 5-Years
-3%
CAGR 10-Years
7%
Johnson & Johnson
NYSE:JNJ
PP&E Gross
$24.5B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
4%
Bristol-Myers Squibb Co
NYSE:BMY
PP&E Gross
$9.1B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
8%
Pfizer Inc
NYSE:PFE
PP&E Gross
$19.3B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
PP&E Gross
$25.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
PP&E Gross
$24.7B
CAGR 3-Years
34%
CAGR 5-Years
23%
CAGR 10-Years
12%
No Stocks Found

Pacira Biosciences Inc
Glance View

Market Cap
1B USD
Industry
Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

PCRX Intrinsic Value
80.886 USD
Undervaluation 69%
Intrinsic Value
Price $25.105

See Also

What is Pacira Biosciences Inc's PP&E Gross?
PP&E Gross
182.5m USD

Based on the financial report for Dec 31, 2025, Pacira Biosciences Inc's PP&E Gross amounts to 182.5m USD.

What is Pacira Biosciences Inc's PP&E Gross growth rate?
PP&E Gross CAGR 10Y
7%

Over the last year, the PP&E Gross growth was -16%. The average annual PP&E Gross growth rates for Pacira Biosciences Inc have been -10% over the past three years , -3% over the past five years , and 7% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett